- Novartis has announced plans for a 56,200-square-foot API manufacturing facility in Morrisville, North Carolina, representing its seventh new US facility within a year of its $23bn investment commitment.
- The facility, backed by a $220m investment, is expected to create more than 700 jobs in Durham and Wake Counties by the end of 2030.
Novartis has announced plans to build a new active pharmaceutical ingredient (API) manufacturing facility in Morrisville, North Carolina, focused on solid dosage tablets, capsules, and RNA therapeutics. The announcement, made on April 30, 2026, marks the seventh new facility planned as part of the company’s $23bn commitment to US-based manufacturing, research and development, first announced approximately one year ago.
The 56,200-square-foot facility will be located at Pathway Triangle and represents a $220m investment, in addition to a previously announced $231m commitment at the same site. The project is expected to create more than 700 new jobs in Durham and Wake Counties by the end of 2030, and will expand Novartis’s presence in North Carolina to five facilities across three sites.
“Last year we committed to adding seven new facilities in the US, and today we finalize our plans to expand our US manufacturing and R&D footprint in the US,” said Vas Narasimhan, CEO of Novartis. “By building a connected, end-to-end footprint, we are strengthening our ability to locally develop, produce, and deliver medicines at scale, enabling timely access to innovation for patients in the US.”
The Morrisville facility forms part of a broader series of investments made since April 2025, which have included new radioligand therapy (RLT) manufacturing sites in Denton, Texas, and Winter Park, Florida; the opening of an RLT facility in Carlsbad, California; the groundbreaking of a flagship manufacturing hub in North Carolina; and the opening of a biomedical research center in San Diego, California. Existing RLT facilities in Indianapolis, Indiana, and Millburn, New Jersey are also undergoing expansion.
The company states it is on track to establish end-to-end manufacturing for all advanced technology platforms in the US, including small and large molecules, radioligand therapies, RNA therapeutics, and cell and gene therapies, which it describes as a first in its history.
